Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging

Abstract Background In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal DOTA-linker structure that provides quantitative labeling yields, diverse...

Full description

Bibliographic Details
Published in:	EJNMMI Research
Main Authors:	Elisabeth Eppard, Ana de la Fuente, Nicole Mohr, Mareli Allmeroth, Rudolf Zentel, Matthias Miederer, Stefanie Pektor, Frank Rösch
Format:	Article
Language:	English
Published:	SpringerOpen 2018-02-01
Subjects:	DOTA-HPMA conjugates Theranostic Radiolabeling Gallium-68 Scandium-44 Lutetium-177
Online Access:	http://link.springer.com/article/10.1186/s13550-018-0372-x

Similar Items

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA<sup>5</sup>.SA.FAPi and DOTA.SA.FAPi
by: Euy Sung Moon, et al.
Published: (2021-06-01)

Side by side comparison of NOTA and DOTA for conjugation efficiency, gallium-68 labeling, and in vivo biodistribution of anti-mesothelin sdAb A1-His
by: Émilien N’Guessan, et al.
Published: (2025-08-01)

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
by: Maryana Handula, et al.
Published: (2023-06-01)

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agents
by: Evangelia-Alexandra Salvanou, et al.
Published: (2022-07-01)

Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
by: Jason P. Meier, et al.
Published: (2025-06-01)

Production of high purity 47Sc from proton irradiation of natural vanadium targets
by: Shelbie Jaylene Cingoranelli, et al.
Published: (2024-12-01)

Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters
by: William Hunt, et al.
Published: (2025-07-01)

Scandium Radioisotopes—Toward New Targets and Imaging Modalities
by: Krzysztof Kilian, et al.
Published: (2023-11-01)

<sup>177</sup>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
by: Evangelia-Alexandra Salvanou, et al.
Published: (2024-02-01)

Optimizing Standardization Systems and Standardizing Clinical Practice: Interpretation of Quality Standards for Medical 68Ge/68Ga Generators and 68Ga Radiopharmaceuticals and Quality Standards for Medical 177Lu and Its Radiopharmaceuticals
by: LAI Yuxin, et al.
Published: (2025-07-01)

Synthesis and Evaluation of <sup>68</sup>Ga- and <sup>177</sup>Lu-Labeled [diF-Pro<sup>14</sup>]Bombesin(6−14) Analogs for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer
by: Lei Wang, et al.
Published: (2025-02-01)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023-05-01)

Optimization of PSMA-I&T radiolabeling with 177Lu
by: Luiza Mascarenhas Balieiro, et al.
Published: (2025-06-01)

Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the <sup>68</sup>Ga- and <sup>177</sup>Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)<sub>2</sub>
by: Tilman Läppchen, et al.
Published: (2024-06-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates
by: K. Yavari, et al.
Published: (2023-09-01)

Mono‐Ethyl‐Phosphonates: Functional Group Masking Strategy to Stabilize and Optimize the Pharmacokinetics of Rare Earth Radiochelates
by: Jennifer N. Whetter, et al.
Published: (2025-07-01)

HPMA Copolymers: A Versatile Platform for Targeted Peptide Drug Delivery
by: Ya Li, et al.
Published: (2025-04-01)

Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
by: Emile B. Veenstra, et al.
Published: (2022-06-01)

Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [<sup>177</sup>Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model
by: Judith Anna Delage, et al.
Published: (2021-01-01)

Preclinical Lutetium-177 Intracellular Dosimetry of Target Cancers in Radionuclide Therapy
by: Aleksandr S. Lunev, et al.
Published: (2025-07-01)

(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
by: Irina Velikyan
Published: (2020-03-01)

DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis—Challenges and Critical Points in Implementation into Clinical Routine
by: Michael Meisenheimer, et al.
Published: (2020-06-01)

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
by: Keamogetswe Ramonaheng, et al.
Published: (2024-03-01)

Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol
by: Elisabeth Eppard, et al.
Published: (2016-04-01)

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023-08-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
by: Louise Emmett, et al.
Published: (2017-03-01)

Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study
by: Júlia Kudláčová, et al.
Published: (2020-12-01)

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
by: Hongmei Li, et al.
Published: (2024-03-01)

Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology
by: Martha Sahylí Ortega Pijeira, et al.
Published: (2022-04-01)

Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
by: M. Meckel, et al.
Published: (2016-09-01)

Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide
by: Hua Yang, et al.
Published: (2021-01-01)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
by: Teresa Monserrat Fuertes, et al.
Published: (2023-09-01)

Development of an ELISA for Measurement of Urinary 3-Hydroxypropyl Mercapturic Acid (3-HPMA), the Marker of Stroke
by: Akihiko Sakamoto, et al.
Published: (2020-08-01)

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
by: Ashleigh Hull, et al.
Published: (2023-08-01)

How much do 68Ga-, 177Lu- and 131I-based radiopharmaceuticals contribute to the global radiation exposure of nuclear medicine staff?
by: L. Struelens, et al.
Published: (2024-11-01)